Monday Pre-Market Insights: Pluristem Therapeutics Inc. (PSTI), Juno Therapeutics Inc (JUNO), OraSure Technologies, Inc (OSUR), Synergy Pharmaceuticals Inc (SGYP)
Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares rose 8.58% to $2.91 after the biopharmaceutical company announced that its PLX cells were selected for the Adaptive Pathways pilot project through the European Medicines Agency. The pilot project is part of the EMA’s initiative to increase timely access to new medications.
Juno Therapeutics Inc (NASDAQ:JUNO) shares increased 5.46% to $45.74 after the pharmaceutical company announced it will be acquiring Stage Cell Therapeutics GmbH, a smaller German biotechnology company. Juno will benefit from Stage’s cell selection and activation technology.
OraSure Technologies, Inc. (NASDAQ:OSUR) shares increased more than 10% in pre-market trading on Monday to $6.60 following the company’s announcement that CEO Douglas A. Michels will be speaking at the 2015 UBS Global Healthcare Conference. Michels is speaking today at 10:00 AM in New York.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are up more than 15% to $4.05 after John Paulson’s hedge fund, Paulson & Co., bought more than 2 million shares of the pharmaceutical company throughout 1Q15. Paulson’s hedge fund now has slightly more than a 2% stake in Synergy.